- BridgeBio to host investor call today (October 17, 2022) at 1:30 pm ET to discuss its two most advanced RAS precision oncology programs – KRASG12C GTP/GDP dual inhibitor development candidate
Daré Bioscience Inc (NASDAQ:DARE) announced topline efficacy results from its Phase 1/2 trial of DARE-HRT1. DARE-HRT1 is a novel, investigational intravaginal…
Sage Therapeutics Inc (NASDAQ:SAGE) and Biogen Inc (NASDAQ:BIIB) presented additional data from the Phase 3 SKYLARK Study of zuranolone in adult women with…